Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Urinary Bladder Neoplasms 4Mesothelioma, Malignant 4Urethral Neoplasms 3Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neuroblastoma 3Medulloblastoma 3Ganglioneuroblastoma 3Cholangiocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Ureteral Neoplasms 2Tongue Neoplasms 2Prostatic Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Transitional Cell 2Brenner Tumor 2Vomiting 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sertoli-Leydig Cell Tumor 1

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Bladder Urothelial Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡